Improving quality of life through innovations in urology.
Urovant Sciences
Vibegron
Our lead product candidate, vibegron, is an investigational oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS).
Latest News
The latest posts and articles
-
Urovant Sciences Reports 2019 Second Fiscal...
on November 5, 2019
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Nov. 5, 2019-- Urovant Sciences (Nasdaq: […]
Read Latest Post -
Urovant Sciences Secures Substantial...
on October 31, 2019
Sumitomo Dainippon Pharma has committed to provide an initial $200 million , low-interest, […]
Read Latest Post -
Urovant Sciences to Report 2019 Second...
on October 29, 2019
IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Oct. 29, 2019-- Urovant Sciences […]
Read Latest Post
Copyright 2018 © All Rights Reserved